Ann: Clinical Progress on IHL-216A for TBI and CTE, page-21

Nothing that already hasnt been said in this thread and tbh should be already well known unless you have your head in the sand.

Out of the many pot stocks on the ASX, I wonder how many have their strategy towards TRULY differentiated products that are NEW cannabinoids.
Err... Leaving this as it is. IMO will expect many MM investors to move over to IHL once they realize their companies simply aren't employing the right strategy or have the right management... But they will come at a massive premium to us of course. Inevitable.